Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Clinical Drug Investigation|February 1, 2015
Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeksRomina Quercia, Jeremy Roberts, Louise Martin-Carpenter, et al.
Journal of Virology|July 17, 2009
Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypesRomina Quercia, Elisabeth Dam, Danielle Perez-Bercoff, et al.
HIV Clinical Trials|June 29, 2005
Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-upRomina Quercia, Elisabeth Garnier, Virginie Ferré, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 24, 2018
Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 InfectionRomina Quercia, Carlo-Federico Perno, Justin Koteff, et al.
Infectious Diseases and Therapy|April 12, 2024
Ritonavir: 25 Years' Experience of Concomitant Medication Management. A Narrative ReviewRomina Quercia, Giovanni Di Perri, Carolina Pein, et al.
The Journal of Infectious Diseases|November 19, 2003
Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapyEvan Wood, Robert S Hogg, Benita Yip, et al.
Infectious Diseases and Therapy|October 27, 2024
Pharmacovigilance of Drug-Drug Interactions with Nirmatrelvir/RitonavirVictoria Hendrick, Erast Pohorylo, Lubna Merchant, et al.
Plos Pathogens|March 21, 2009
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness lossElisabeth Dam, Romina Quercia, Bärbel Glass, et al.
AIDS Research and Human Retroviruses|September 12, 2019
Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 InfectionMarta Boffito, Laura Waters, Pedro Cahn, et al.
Open Forum Infectious Diseases|September 1, 2022
Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional SubgroupsM Keith Rawlings, Emilio Letang, Romina Quercia, et al.
Pageof 2